An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi

Streptococcus Pneumoniae Clinical Trial

— PAVE  

Official title:

Pneumococcal Conjugate Vaccine 13 (PCV13) Schedule Change From 3+0 to 2+1 to Accelerate Reduction in Pneumococcal Vaccine Serotype Carriage in Blantyre, Malawi: an Effectiveness Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04078997
• Other study ID #: 5270
• Secondary ID: OPP1208803
• Status: Recruiting
• Start date: March 16, 2022
• Est. completion date: September 30, 2024

Study information

• Verified date: January 2024
• Source: University of Liverpool
• Contact: Todd Swarthout, PhD
• Phone: +31 (0)6 2788 2862
• Email: t.swarthout[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pneumococcal conjugate vaccines (PCV) have been shown to be effective against invasive pneumococcal disease (IPD; including pneumococcal meningitis and sepsis) and all-cause mortality among young children when introduced into infant expanded programs on immunization (EPI). Colonization of the nasopharynx by Streptococcus pneumoniae is a necessary prerequisite to pneumococcal disease. Critically important to the population impact of PCV is therefore reducing vaccine serotype (VT) carriage prevalence, and therefore reducing both disease and onward transmission to vulnerable individuals. Thus, as well as protecting the vaccinated individual (direct protection), PCV confers indirect protection (herd immunity) to unvaccinated populations and to vaccinated individuals who have insufficient protective immunity.

While the ability of PCVs to induce herd immunity has been strong enough to control pneumococcal carriage in industrialized countries, such benefits have not been as marked in low-income countries. Carriage surveillance in Blantyre, Malawi from 4 to 7 years post-vaccine implementation shows persistent VT carriage. With the exception of South Africa, most sub-Saharan African countries, including Malawi, have introduced PCV using a 3+0 schedule. Whether the WHO-approved 2+1 schedule will maximize vaccine-induced protection has been identified as a research gap by the WHO. In this context, the Malawian Ministry of Health (MoH) and the National Immunizations Technical Advisory Committee (NITAG) are seeking evidence of adequate superiority of a 2+1 schedule to inform a change to the current Malawi EPI schedule.

HYPOTHESIS: Prolonging the period of vaccine-induced protection with a booster vaccine dose at 9 months will extend the period of low VT carriage, hence providing longer direct vaccine-induced protection as well as boosting the indirect herd immunity effect.

METHOD: The MoH will implement an evaluation, comparing a 2+1 to the current 3+0 PCV13 vaccine schedule in Blantyre District. This will use a pragmatic health centre-based randomization protocol, implemented within the scope of the EPI programme. This MoH-led change will be evaluated in partnership with the Malawi Liverpool Wellcome Trust Clinical Research Programme. Community carriage surveillance will be undertaken at 15 and 33 months after the introduction of the 2+1 schedule.

The primary endpoint will be VT carriage prevalence among children 15-24 months of age 36 months after schedule change. Other targeted study groups will include children aged 5-10 years who have received PCV13 on a 3+0 schedule, children aged 9 months who have received PCV13 in either a 3+0 or a 2+0 schedule, and HIV-infected adults aged 18-40 years receiving ART and PCV13-unvaccinated.

EXPECTED FINDINGS: Data will inform NITAG decisions on national vaccine policy, with implications at a national, regional and global level.

Description:

STUDY TYPE: Pragmatic health center-based evaluation to compare effectiveness of a MoH-mandated structured PCV13 schedule change from 3+0 to 2+1 dosing in a high disease burden setting in Malawi PROBLEM: Streptococcus pneumoniae is a leading cause of childhood pneumonia, meningitis, and bacteremia in sub-Saharan Africa. Pneumococcal conjugate vaccines (PCV) the commonest pneumococcal serotypes have been shown to be effective against pneumococcal meningitis and sepsis, so-called invasive pneumococcal disease (IPD), pneumonia, and all-cause mortality among young children when introduced into infant expanded programs on immunization (EPI). Colonization of the nasopharynx by Streptococcus pneumoniae is a necessary prerequisite to pneumococcal disease. Critically important to the population impact of PCV is therefore reducing vaccine serotype (VT) carriage prevalence, and therefore reducing both disease and onward transmission to vulnerable individuals. Thus, as well as protecting the vaccinated individual (direct protection), PCV confers indirect protection (herd immunity) to unvaccinated populations and to vaccinated individuals who have insufficient protective immunity.

While the ability of PCVs to induce herd immunity has been strong enough to control pneumococcal carriage and disease in industrialized countries, such benefits have not been as marked in low-income countries. In Malawi, the introduction of the PCV13 achieved an approximate 70% reduction in IPD among vaccinated children, and an estimated 35% fall in all-cause mortality among vaccinated children. However, carriage surveillance 4 to 7 years post-vaccine implementation shows persistent VT carriage. Data suggests that most of the vaccine's direct benefit occurs in the first 12 months of life, further suggesting that vaccine-induced protection against pneumococcal disease and colonization wanes rapidly under the current 3+0 schedule. With the exception of South Africa, most sub-Saharan African countries, including Malawi, have introduced PCV using a 3+0 schedule (doses at 6, 10, and 14 weeks of age). Whether the 2+1 schedule (6, 10 weeks and 9 months of age) will maximize vaccine-induced protection has been identified as a research gap by the WHO. There is a dearth of head-to-head studies directly comparing these two schedules. In this context, the Malawian Ministry of Health (MoH) and the National Immunizations Technical Advisory Committee (NITAG) are seeking evidence of adequate superiority of a 2+1 schedule to inform a change to the current Malawi EPI schedule.

HYPOTHESIS: Prolonging the period of vaccine-induced protection with a booster vaccine dose at 9 months will extend the period of low VT carriage, hence providing longer direct vaccine-induced protection as well as boosting the indirect herd immunity effect.

METHOD: The MoH will implement a 2+1 PCV13 vaccine schedule change in Blantyre District. A comparison with the ongoing 3+0 schedule will use a pragmatic health centre-based randomization protocol, with 10 centres continuing with the current 3+0 and 10 implementing the WHO-approved 2+1 schedule. This change will be implemented within the scope of the EPI, subjected to EPI standard procedures for delivery, monitoring, and assessment. This MoH-led change will be evaluated as part of a longstanding partnership with the Malawi Liverpool Wellcome Trust Clinical Research Programme. Researchers will undertake two population based pneumococcal carriage surveys in these 20 health centre catchment areas, at 15 and 33 months after the introduction of the 2+1 schedule.

PRIMARY OUTCOME: VT carriage prevalence among children 15-24 months of age 36 months after schedule change.

SECONDARY OUTCOMES: VT carriage prevalence among children 5-10 years old, among HIV infected adults 18-40 years, add among children 9 months old. Others include prevalence of multiple serotype carriage, and completeness of 3 doses PCV13.

POPULATION: Children who are aged 15-24 months, residents of Blantyre District, and who have received PCV13 in either a 3+0 or a 2+1 schedule (recruited from households); Children aged 5-10 years who have received PCV13 on a 3+0 schedule (recruited from schools); children aged 9 months, who have received PCV13 in either a 3+0 or a 2+0 schedule (recruited from health centres at routine 9-month visit); HIV-infected adults aged 18-40 years receiving ART and PCV13-unvaccinated (recruited from the Queen Elizabeth Central Hospital (QECH) HIV/ART Clinic) EXPECTED FINDINGS: Data will inform NITAG decisions on national vaccine policy, with implications at a national, regional and global level. Results will be disseminated through peer-reviewed publications, scientific conferences, and other relevant stakeholder and policymakers' meetings. This work will strengthen collaboration between relevant government and academic institutions, provide research training for MoH staff and early-career researchers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5900
• Est. completion date: September 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Months to 40 Years

Eligibility

INCLUSION CRITERIA

PCV13-vaccinated children, 15-24 months of age (schedule 2+1 or 3+1):

• Aged between 15-24 month

• Permanent resident in Blantyre District

• Parent/legal guardian consent for the child to have a NP swab taken

• Evidence of having received a full schedule of PCV13 vaccination recorded in the health passport and which schedule given

PCV13-vaccinated children, 9 months of age (schedule 2+0 or 3+0):

• Aged 9 months

• Permanent resident in Blantyre District

• Parent/legal guardian consent for the child to have a NP swab taken

• Evidence of having received either a full 3+0 schedule or both primary doses (at approximately 6 and 14 weeks of age) of the 2+1 schedule of PCV13 vaccination recorded in the health passport

PCV13-vaccinated children, 5-10 years of age (schedule 3+0):

• Aged between 5-10 years

• Parent/legal guardian consent for the child to have a NP swab taken

• If the child is =8 years old, child assent to have a NP swab taken

• Either verbal or documented evidence of having received primary immunization with PCV

PCV13-unvaccinated HIV-infected adults on ART 18 - 40 years of age:

• Aged 18-40 years

EXCLUSION CRITERIA:

For all participants:

• Current TB treatment

• Pneumonia hospitalization <14 days before study enrolment

• Terminal illness

For Children:

• No parental/legal guardian consent

• No child assent (children aged >8 years old)

• Having received antibiotic treatment <14 days before study enrolment

For Adults:

• Unable or unwilling to provide consent

• Prior vaccination with pneumococcal vaccine

Related Conditions & MeSH terms

• 13-valent Pneumococcal Vaccine
• Pneumonia, Pneumococcal
• Streptococcus Pneumoniae

Intervention

Other:
• nasopharyngeal swab
A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.

Locations

Country	Name	City	State
Malawi	Malawi-Liverpool-Wellcome Research Programme	Blantyre	Chichiri

Sponsors (8)

Lead Sponsor	Collaborator
University of Liverpool	Blantyre District Health Office, Liverpool School of Tropical Medicine, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Ministry of Health, Malawi, UNICEF, University College, London, World Health Organization

Country where clinical trial is conducted

Malawi, 

References & Publications (1)

Swarthout TD, Ibarz-Pavon A, Kawalazira G, Sinjani G, Chirombo J, Gori A, Chalusa P, Bonomali F, Nyirenda R, Bulla E, Brown C, Msefula J, Banda M, Kachala J, Mwansambo C, Henrion MY, Gordon SB, French N, Heyderman RS. A pragmatic health centre-based evaluation comparing the effectiveness of a PCV13 schedule change from 3+0 to 2+1 in a high pneumococcal carriage and disease burden setting in Malawi: a study protocol. BMJ Open. 2021 Jun 17;11(6):e050312. doi: 10.1136/bmjopen-2021-050312. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vaccine-type pneumococcal carriage prevalence among children 15-24 months old		36 months after 2+1 vaccine schedule implementation
Secondary	Vaccine-type pneumococcal carriage prevalence among children 5-10 years old		36 months after 2+1 vaccine schedule implementation
Secondary	Vaccine-type pneumococcal carriage prevalence among HIV infected adults 18-40 years old		36 months after 2+1 vaccine schedule implementation
Secondary	Vaccine-type pneumococcal carriage prevalence among children 9 months old		9 months after 2+1 vaccine schedule implementation
Secondary	Prevalence of multiple pneumococcal serotype carriage		36 months after 2+1 vaccine schedule implementation
Secondary	Proportion of children receiving a full 3-dose PCV13 vaccination schedule		36 months after 2+1 vaccine schedule implementation